Emory University researchers reported that short-course venetoclax, a BCL-2 inhibitor approved for blood cancers, reduced the intact SIV reservoir in rhesus macaques when administered at the start of antiretroviral therapy. Published in Nature Microbiology, the study tracked reservoir changes over nearly 10 months, with reductions seen in blood and also in lymph nodes—key tissue sites for persistence.